# Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

> **NCT01127633** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 1457 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Solanezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01127633
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2014-07
- **Final completion:** 2017-02
- **Target enrollment:** 1457 (ACTUAL)
- **Why stopped:** Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.
- **Last updated:** 2019-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01127633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01127633, "Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01127633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*